secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001213900-25-068745
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio to publish video with additional Phase 2 XPro trial findings after AAIC
--------------------------------------------------------------------------------

- Video detailing additional MINDFuL Phase 2 findings of XPro (soluble TNF inhibitor) to be published July 31 at 4 PM ET.
- Trial showed consistent cognitive and biomarker benefit after 6 months in amyloid-beta+ patients with ≥2 inflammatory blood biomarkers.
- Data presented at AAIC July 29 in Toronto; corporate presentation also filed as Exhibit 99.2.
- Dr. Sharon Cohen presented; VP Dr. CJ Barnum cited meaningful changes in short trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025068745/0001213900-25-068745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025068745/ea0250594-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-068745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer